Eisai Announces New Investigational Data from Study 211 Evaluating the Starting Dose of LENVIMA® (lenvatinib) in Differentiated Thyroid Cancer at ESMO Asia 2020

WOODCLIFF LAKE, N.J., Nov. 20, 2020 /PRNewswire/ — Eisai announced results from Study 211 evaluating the safety and efficacy of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, at two starting doses: the FDA-approved dose of 24 mg once daily…

Continue Reading

HEDGE accordingly